Oorja Bio secured $30 million in a Series A financing led by founding investor Westlake Biopartners to pursue an in-licensing approach targeting idiopathic pulmonary fibrosis and other fibrotic cardiopulmonary indications. The company’s capital plan focuses on moving pipeline candidates through early development while evaluating partnership opportunities. The raise signals continued investor appetite for fibrotic disease programs, particularly as companies attempt to build differentiated assets through structured licensing rather than fully internal discovery. For industry observers, the transaction may also influence deal dynamics in the IPF and adjacent pulmonary fibrosis landscape by adding a new buyer and co-developer for early-stage compounds.